Mpox vaccine trial expands to children: a step toward broader protection
NCT ID NCT06549530
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the MVA-BN vaccine in 460 children aged 2 to 12 years, comparing their immune response and safety to adults. All participants receive two doses four weeks apart. The goal is to see if the vaccine can prevent smallpox, mpox, and related orthopoxvirus infections in younger populations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MVA-BN vaccine
What this could lead to
If successful, this could show that the MVA-BN vaccine is safe and effective for children, potentially protecting them from mpox and related viruses.
What could go wrong
This is a Phase 2 trial with only 460 participants, so results may not apply to all children. The vaccine might not produce a strong enough immune response or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX (MPOX) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epicentre Mbarara Research Centre
Mbarara, Uganda
-
Uganda Virus Research Institute
Entebbe, Uganda
-
University of Kinshasa
Kinshasa, Democratic Republic of the Congo